drugset / Trial / NCT00303602

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

NCT00303602

Phase 4 Completed 149 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.

Timeline

Start
2006-03
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 5 mg Other
Subject Olanzapine Small molecule 20 mg Other